CERYVYN THERAPEUTICS LIMITED ADR
WKN: A2QEW7 | ISIN: US68386J2087 | Ticker: UKJ2Siehe auch CERYVYN THERAPEUTICS LIMITED
München
12.08.26 | 08:02
0,035 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.10. | Ceryvyn Therapeutics Moves CYV-101 Lung Disease Program Closer to Clinical Testing | 2 | smallcaps.com.au | ||
| 28.10. | CERYVYN THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 19.10. | CERYVYN THERAPEUTICS LIMITED: Change of Auditor | - | ASX | ||
| 16.10. | CERYVYN THERAPEUTICS LIMITED: Notice of Annual General Meeting/Proxy Form | 1 | ASX | ||
| 13.10. | CERYVYN THERAPEUTICS LIMITED: Change in substantial holding | 1 | ASX | ||
| 08.10. | CERYVYN THERAPEUTICS LIMITED: Change in substantial holding | - | ASX | ||
| CERYVYN THERAPEUTICS LIMITED ADR Aktie jetzt für 0€ handeln | |||||
| 06.10. | CERYVYN THERAPEUTICS LIMITED: Change in substantial holding | - | ASX | ||
| 02.10. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | 2.801 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| 02.10. | CERYVYN THERAPEUTICS LIMITED: Change in substantial holding | - | ASX | ||
| 24.09. | CERYVYN THERAPEUTICS LIMITED: Notification regarding unquoted securities - CYV | - | ASX | ||
| 22.09. | CERYVYN THERAPEUTICS LIMITED: Annual General Meeting Date | 2 | ASX | ||
| 14.09. | CERYVYN THERAPEUTICS LIMITED: Notification regarding unquoted securities - CYV | - | ASX | ||
| 08.09. | CERYVYN THERAPEUTICS LIMITED: Proposed issue of securities - CYV | - | ASX | ||
| 01.09. | CERYVYN THERAPEUTICS LIMITED: Proposed issue of securities - CYV | - | ASX | ||
| 31.08. | CERYVYN THERAPEUTICS LIMITED: Appendix 4G and Corporate Governance Statement | - | ASX | ||
| 31.08. | CERYVYN THERAPEUTICS LIMITED: Appendix 4E and 2026 Annual Report | - | ASX | ||
| 21.08. | CERYVYN THERAPEUTICS LIMITED: Notification regarding unquoted securities - CYV | 1 | ASX | ||
| 27.07. | CERYVYN THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 17.07. | CERYVYN THERAPEUTICS LIMITED: Update to Executive Chair Remuneration Arrangements | - | ASX | ||
| 13.07. | CERYVYN THERAPEUTICS LIMITED: Notification of cessation of securities - CYV | - | ASX |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 7,170 | +2,72 % | This Palatin Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday | ||
| COSCIENS BIOPHARMA | 5,200 | 0,00 % | XFRA ET80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 89,32 | -3,19 % | Halozyme Therapeutics, Inc.: U.S. FDA Approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE Technology for the Treatment of Advanced Head and Neck Cancer | Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 11,340 | +1,43 % | StoneX raises AbCellera Biologics stock price target to $15 | ||
| GLOW LIFETECH | 0,016 | -5,88 % | Smallcap Discoveries: Glow Lifetech Corp. to Present at the Annual Smallcap Discoveries Conference in Vancouver | Toronto, Ontario--(Newsfile Corp. - September 24, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce that it will be participating in... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 343,60 | -0,81 % | Bio-Rad reaffirms 2026 currency-neutral revenue growth at (-3%) to 0.5% while targeting non-GAAP operating margin in upper half of 10% to 12% range | ||
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent Strategy | Company expands team, university partnerships, and internship programs to build long-term biologics talent pipeline.TUSTIN, Calif., May 18, 2026 /PRNewswire/ -- Avid Bioservices, a leading... ► Artikel lesen | |
| BIOLINERX | 1,110 | -10,48 % | BioLineRx Ltd.: BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update | - Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September -
- Announced new data... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 2,138 | -0,28 % | Minerva Neurosciences, Inc. - 10-Q, Quarterly Report | ||
| WHITEHAWK THERAPEUTICS | 2,700 | -0,74 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights | On track to report initial Phase 1 data from HWK-007 and HWK-016 in 1H'27Initiated Phase 1 trial for HWK-206 in the U.S., the third Whitehawk program to enter the clinic in the last 12 months; HWK-206... ► Artikel lesen | |
| INNOVENT BIOLOGICS | 10,110 | +1,00 % | Abnehmpillen-Boom: Aktie im Plus: Eli Lilly gelingt ein wichtiger Durchbruch | © Foto: Sascha Lotz/dpaEli Lilly sichert sich einen Vorsprung in China. Mit einer neuen Abnehmpille greift der US-Konzern einen Milliardenmarkt an und setzt Novo Nordisk unter Druck Enthaltene Werte:... ► Artikel lesen | |
| OVID THERAPEUTICS | 2,520 | +0,80 % | Ovid Therapeutics GAAP EPS of -$0.10 misses by $0.02 | ||
| GEOVAX LABS | 0,111 | -0,18 % | EQS-News: GeoVax, Inc.: GeoVax Announces 1-for-24 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement | EQS-News: GeoVax, Inc.
/ Key word(s): Financial
GeoVax Announces 1-for-24 Reverse Stock Split to Regain Compliance With Nasdaq Minimum Bid Requirement 09.11.2026 / 14:30 CET/CEST
The... ► Artikel lesen | |
| COCRYSTAL | 0,900 | -5,76 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors | BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 8,300 | -2,35 % | Precision BioSciences announces $125M public offering; shares up |
Das Unternehmen CERYVYN THERAPEUTICS LIMITED ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,035 Euro. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERYVYN THERAPEUTICS LIMITED ADR finden Sie auf Wallstreet Online.